OMALIZUMAB

( DrugBank: Omalizumab / KEGG DRUG: Omalizumab )

7 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
53	Sjogren syndrome	1
65	Primary immunodeficiency	1
98	Eosinophilic gastrointestinal disease	3

ID	Disease name (Link within this page)	Number of trials
162	Pemphigoid	2
226	Interstitial cystitis with Hunners ulcer	1
299	Cystic fibrosis	7

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-017306-36-NL (EUCTR)	19/11/2010	19/08/2010	ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. - TIGER	ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. - TIGER	RHEUMATOID ARTHRITIS MedDRA version: 12.1;Level: LLT;Classification code 10003268;Term: Arthritis rh ...	Trade Name: Xolair Product Name: OMALIZUMAB INN or Proposed INN: OMALIZUMAB Other descriptive name: Xol ...	Leiden University Medical Center, Department of Rheumatology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

First Previous1Next Last

53. Sjogren syndrome

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01716312 (ClinicalTrials.gov)	January 8, 2014	23/10/2012	Omalizumab for Lupus	A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evalu ...	Systemic Lupus Erthematosus;Sjogren's Syndrome	Drug: Omalizumab	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	18 Years	100 Years	All	17	Phase 1	United States

First Previous1Next Last

65. Primary immunodeficiency

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00260702 (ClinicalTrials.gov)	November 24, 2005	1/12/2005	Omalizumab to Treat Hyper-IgE (Job's) Syndrome	Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome	Hyper-IgE Syndrome;Job's Syndrome	Drug: Omalizumab (Xolair)	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	6 Years	76 Years	All	1	Phase 1	United States

First Previous1Next Last

98. Eosinophilic gastrointestinal disease

Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01040598 (ClinicalTrials.gov)	June 2009	27/12/2009	Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model	Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model	Eosinophilic Esophagitis	Biological: Omalizumab	O & O Alpan LLC	Genentech, Inc.	Completed	12 Years	76 Years	Both	19	Phase 1	United States
2	NCT00123630 (ClinicalTrials.gov)	November 2005	21/7/2005	A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab	A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab	Esophagitis	Drug: omalizumab;Drug: Placebo	University of Utah	Novartis Pharmaceuticals	Completed	12 Years	60 Years	All	30	Phase 2	United States
3	NCT00084097 (ClinicalTrials.gov)	June 2, 2004	5/6/2004	Omalizumab to Treat Eosinophilic Gastroenteritis	Pilot Study of Omalizumab in Eosinophilic Gastroenteritis	Gastroenteritis	Drug: Omalizumab	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	12 Years	76 Years	All	30	Phase 2	United States

First Previous1Next Last

162. Pemphigoid

Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04128176 (ClinicalTrials.gov)	May 25, 2023	12/10/2019	Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumabin Pati ...	Bullous Pemphigoid	Drug: Rituximab combined with Omalizumab	University of California, Davis	NULL	Not yet recruiting	18 Years	90 Years	All	15	Phase 3	United States
2	NCT00472030 (ClinicalTrials.gov)	August 2007	8/5/2007	Efficacy and Safety of Omalizumab in Bullous Pemphigoid	An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid	Bullous Pemphigoid	Drug: Omalizumab;Drug: prednisone	University of Iowa	Genentech, Inc.	Completed	18 Years	N/A	All	2	Phase 4	United States

First Previous1Next Last

226. Interstitial cystitis with Hunners ulcer

Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01294878 (ClinicalTrials.gov)	March 2009	11/2/2011	Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome	Explorative Study on the Use of Omalizumabin Patients Suffering From Interstitial Cystitis/Painful B ...	Interstitial Cystitis;Painful Bladder Syndrome	Drug: omalizumab	IRCCS Policlinico S. Matteo	NULL	Completed	18 Years	N/A	Female	3	Phase 3	Italy

First Previous1Next Last

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-006648-23-IE (EUCTR)	11/12/2009	15/04/2009	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version ...	Trade Name: Xolair	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 4	Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom
2	EUCTR2007-006648-23-IT (EUCTR)	06/08/2009	22/05/2009	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis MedDRA version: ...	Trade Name: XOLAIR INN or Proposed INN: Omalizumab	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy
3	EUCTR2007-006648-23-NL (EUCTR)	08/06/2009	03/09/2008	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version ...	Trade Name: Xolair INN or Proposed INN: omalizumab Other descriptive name: Recombinant humanized monoc ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy
4	EUCTR2007-006648-23-GB (EUCTR)	27/02/2009	09/10/2008	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version ...	Trade Name: Xolair INN or Proposed INN: Omalizumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		Germany;United Kingdom;Netherlands;Belgium;Ireland;Italy
5	EUCTR2007-006648-23-DE (EUCTR)	12/11/2008	15/08/2008	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version ...	Trade Name: Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung Product ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy
6	NCT00787917 (ClinicalTrials.gov)	November 2008	7/11/2008	An Exploratory Study to Assess Multiple Doses of Omalizumabin Patients With Cystic Fibrosis Complica ...	An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multipl ...	Cystic Fibrosis;Allergic Bronchopulmonary Aspergillosis	Drug: Omalizumab;Drug: Placebo;Drug: Itraconazole	Novartis Pharmaceuticals	NULL	Terminated	12 Years	N/A	All	14	Phase 4	Belgium;Germany;Italy;Netherlands;United Kingdom
7	EUCTR2007-006648-23-BE (EUCTR)	30/09/2008	28/08/2008	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multipl ...	Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version ...	Trade Name: Xolair INN or Proposed INN: omalizumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy

First Previous1Next Last